{
    "organizations": [],
    "uuid": "7958e09c376737472da0854fc40d280304aac8a6",
    "author": "",
    "url": "https://www.reuters.com/article/brief-abbvie-announces-results-from-phas/brief-abbvie-announces-results-from-phase-2-study-evaluating-rovalpituzumab-tesirine-for-third-line-treatment-of-patients-with-dll3-expressing-relapsed-refractory-small-cell-lung-cancer-idUSFWN1R40SD",
    "ord_in_thread": 0,
    "title": "BRIEF-Abbvie Announces Results From Phase 2 Study Evaluating Rovalpituzumab Tesirine For Third-Line Treatment Of Patients With DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News March 22, 2018 / 12:53 PM / Updated 7 minutes ago BRIEF-Abbvie Announces Results From Phase 2 Study Evaluating Rovalpituzumab Tesirine For Third-Line Treatment Of Patients With DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer Reuters Staff 1 Min Read March 22 (Reuters) - Abbvie Inc: * ABBVIE ANNOUNCES RESULTS FROM PHASE 2 STUDY EVALUATING ROVALPITUZUMAB TESIRINE (ROVA-T) FOR THIRD-LINE TREATMENT OF PATIENTS WITH DLL3-EXPRESSING RELAPSED/REFRACTORY SMALL CELL LUNG CANCER * ABBVIE INC - ‍WILL NOT SEEK ACCELERATED APPROVAL FOR ROVA-T IN THIRD-LINE RELAPSED/REFRACTORY SMALL CELL LUNG CANCER​ * ABBVIE INC - ‍SAFETY DATA IN TRINITY STUDY WERE CONSISTENT WITH PREVIOUSLY REPORTED STUDIES OF ROVA-T​ * ABBVIE INC - ‍ROVA-T DEMONSTRATED SINGLE AGENT RESPONSES IN ADVANCED SCLC PATIENTS​ * ABBVIE INC - ONGOING PHASE 3 STUDIES, MERU AND TAHOE, WILL CONTINUE TO INVESTIGATE ROVA-T IN FIRST- AND SECOND-LINE SCLC Source text for Eikon: Further company coverage:",
    "published": "2018-03-22T14:49:00.000+02:00",
    "crawled": "2018-03-22T15:04:49.017+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "result",
        "phase",
        "study",
        "evaluating",
        "rovalpituzumab",
        "tesirine",
        "treatment",
        "patient",
        "small",
        "cell",
        "lung",
        "cancer",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "abbvie",
        "inc",
        "abbvie",
        "announces",
        "result",
        "phase",
        "study",
        "evaluating",
        "rovalpituzumab",
        "tesirine",
        "treatment",
        "patient",
        "small",
        "cell",
        "lung",
        "cancer",
        "abbvie",
        "inc",
        "seek",
        "accelerated",
        "approval",
        "small",
        "cell",
        "lung",
        "abbvie",
        "inc",
        "data",
        "trinity",
        "study",
        "consistent",
        "previously",
        "reported",
        "study",
        "abbvie",
        "inc",
        "demonstrated",
        "single",
        "agent",
        "response",
        "advanced",
        "sclc",
        "abbvie",
        "inc",
        "ongoing",
        "phase",
        "study",
        "meru",
        "tahoe",
        "continue",
        "investigate",
        "sclc",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}